FDA accepts Sandoz biosimilar application

29-07-2014

FDA accepts Sandoz biosimilar application

41 / Shutterstock.com

US officials have accepted an application by Novartis to market a biosimilar of Amgen’s Neupogen (filgrastim) drug, a move thought to be the first of its kind.


Sandoz, Amgen, biosimilar, FDA, Neupogen

More on this story

FDA gives nod to Novartis cancer biosimilar
05-01-2015

LSIPR